Image

Global Metastatic Melanoma Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Metastatic Melanoma Market, By Diagnosis (Physical Examination, Biopsy and Imaging Test), Treatment (Chemotherapy, Radiation, Surgery and Others), Route of Administration (Oral, Parenteral, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Metastatic Melanoma Market

Metastatic Melanoma Market Analysis and Size

The metastatic melanoma market is expected to witness significant growth during the forecast period. According to WHO, about 132,000 skin cancer cases occur annually. There has been a 10% decrease in ozone levels is projected to lead to a rise of 4,500 skin cancer cases worldwide. Early detection of melanoma helps in the treatment and increase survival rates. The rare genetic conditions such as xeroderma pigmentosum also increase the risk of melanoma and it is diagnosed with the biopsy of any skin lesion.

Data Bridge Market Research analyses a growth rate in the metastatic melanoma market in the forecast period 2022-2029. The expected CAGR of metastatic melanoma market is tend to be around 12% in the mentioned forecast period. The market was valued at USD 6.5 billion in 2021, and it would grow upto USD 16.09 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Metastatic Melanoma Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Diagnosis (Physical Examination, Biopsy and Imaging Test), Treatment (Chemotherapy, Radiation, Surgery and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited (India), Sanofi S.A. (France), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.)

Market Opportunities

  • Development of new Biologics
  • Increasing Demand for Retail Pharmacies

Market Definition

Melanoma is a kind of skin cancer wherein cancerous cells develops in pigment-producing cells called melanocytes. It can also affect in eyes and very rarely in the nose or throat. Patient suffering from the melanoma generally develops unusual growth in an existing mole. Metastatic melanoma is the most severe stage (IV) of skin cancer that occurs when the melanoma penetrates the skin and reaches several other parts of the body. People staying at high altitudes or close to the equator are at greater risk of melanoma due to high exposure to UV radiation.

Global Metastatic Melanoma Market

Drivers

  • Notable Developments in terms of Market Players

Recently, there have been some promising and innovative developments in the global melanoma market. The market has observed the presence of several noticeable market players with each of the players competing for more revenue and greater reach. Relentless research and development activities has played a critical role in the expansion of the share of the market and growing revenue for the market players. This boosts the market growth.

  • Increase in Skin Cancer

As per the records of WHO, around 132,000 cases of skin cancer occur each year. Furthermore, a 10% reduction in ozone levels is predicted to lead to an increase of 4,500 skin cancer cases worldwide. This is projected to increase the demand for these drugs during the forecast period.

Opportunities

  • Growing Healthcare Infrastructure and Policies

The presence of large patient pool, having a strong presence of key players, ease of drug availability, a well-established healthcare infrastructure, favorable reimbursement policies in the healthcare system, rise in R&D, and innovation activities and higher adoption of advanced therapeutics may create opportunities for the market.    

  • Development of new Biologics

The major market players in the U.S., Europe, and Asia Pacific which are focusing on the development of new biologics for the treatment of melanoma. For instance, in March 2017, Take a Novel Challenge for Drug Discovery (TaNeDS) was introduced by Daiichi Sankyo Company Limited, as a type of collaborative project aimed at facilitating new drug development through collaborations. In addition, it has a strategic research partnership with AgonOX, Inc. to explore innovative immunotherapy medications for the immuno-oncology market.

 Restraints/Challenges

  • Unavailability of Appropriate Treatments

To treat conditions that are rare, many times all treatments are not available, especially in underdeveloped countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in the hospitals and clinics. Thus, it hampers the market growth.

  • High Cost

The huge expenditure associated with the several treatment methods such as chemotherapy, and targeted therapy which are in high demand in recent years hamper the market growth.

This metastatic melanoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the metastatic melanoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Metastatic Melanoma Market

The pandemic has significantly affected numerous diagnostic methods because of several restrictions and risk exposure of comorbidity patients. A drastic decrease in skin biopsies was seen early in the COVID-19 pandemic, which unreasonably affected the elderly, females, and certain geographic regions. However, efforts have been made by the government to contain the situation in the post-pandemic era.

Recent Development:

In 2020, FDA approved the drug selumetinib of AstraZeneca and Merck & Co. to treat neurofibromatosis type 1, or NF1, a rare and characteristically inherited disease that causes tumors to grow inside nerve sheaths. In addition to this, Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.

Global Metastatic Melanoma Market Scope

The metastatic melanoma market is segmented on the basis of diagnosis, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

  • Physical Examination
  • Biopsy and Imaging Test

Treatment

  • Chemotherapy
  • Radiation
  • Surgery
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Metastatic Melanoma Market Regional Analysis/Insights

The global metastatic melanoma market is analyzed and market size insights and trends are provided by diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global metastatic melanoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global metastatic melanoma market throughout the forecasted period due to the increased prevalence of melanoma and increasing investment in healthcare segment.

North America dominates the market due to latest technology development and presences of variety of innovative drug molecule to enhance the treatment procedure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Metastatic Melanoma Market Share Analysis

The metastatic melanoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to metastatic melanoma market.

Key players operating in the metastatic melanoma market include:

  • Johnson & Johnson Private Limited (U.S.)
  • Mylan N.V. (U.S.)
  • Sun Pharmaceutical Industries Limited(India)
  • Sanofi S.A.( France)
  • Bayer AG (Germany)
  • Lilly (U.S.)
  • Merck & Co., Inc. (U.S.)
  • GSK plc (U.K.)
  • Novartis AG (Switzerland)
  • AbbVie Inc. (U.S.)
  • Bausch Health Companies Inc. (Canada)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Amgen Inc. (U.S.)


SKU-
Why Choose Us


Frequently Asked Questions

The global metastatic melanoma market was USD 6.5 billion in 2021.
The global metastatic melanoma market is projected to grow at a CAGR of 12% during the forecast period of 2022-2029.
North America dominates the market due to latest technology development and presences of variety of innovative drug molecule to enhance the treatment procedure.
Asia-Pacific has been witnessing a positive growth for global metastatic melanoma market throughout the forecasted period due to the increased prevalence of melanoma and increasing investment in healthcare segment.